Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-03-17

FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)

View source ↗

Summary

The FDA approved a supplemental application for a fixed-dose combination of alogliptin benzoate and pioglitazone hydrochloride to treat type 2 diabetes mellitus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alogliptin benzoate (alogliptin benzoate)
  • Pioglitazone hydrochloride (Pioglitazone hydrochloride)

Snippet

SUPPL AP for ALOGLIPTIN AND PIOGLITAZONE (ALOGLIPTIN BENZOATE AND PIOGLITAZONE HYDROCHLORIDE)